Is optimal first-line chemotherapy deliverable in all newly diagnosed ovarian cancers?: A population-based study

O M McNally; E Delaney; R D Petty; M E Cruickshank; A W Hutcheon; D E Parkin

doi:10.1038/sj.bjc.6601071

Is optimal first-line chemotherapy deliverable in all newly diagnosed ovarian cancers? A population-based study

O M McNally, E Delaney, R D Petty, M E Cruickshank, A W Hutcheon, D E Parkin

Research output: Contribution to journal › Article › peer-review

7 Citations (Scopus)

Abstract

NICE guidance recommends the use of paclitaxel and a platinum therapy for all cases of ovarian cancer. We report our experience of treating 133 patients with ovarian cancer over a 3-year period. Where indicated, 91% received chemotherapy. A taxane/platinum combination was found to be appropriate in 63% of patients only.

Original language	English
Pages (from-to)	966-967
Number of pages	2
Journal	British Journal of Cancer
Volume	89
Issue number	6
Early online date	9 Sept 2003
DOIs	https://doi.org/10.1038/sj.bjc.6601071
Publication status	Published - 15 Sept 2003

Keywords

Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols
Carboplatin
Combined Modality Therapy
Female
Humans
Middle Aged
Mixed Tumor, Mullerian
Neoplasm Staging
Neoplasms, Glandular and Epithelial
Ovarian Neoplasms
Paclitaxel
Practice Guidelines as Topic
Prospective Studies
Radiotherapy Dosage
Survival Rate
Taxoids
NICE
Ovarian Cancer
Chemotherapy

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/sj.bjc.6601071

Cite this

@article{6b251fb5b9b3463281ddf66514bb4f90,

title = "Is optimal first-line chemotherapy deliverable in all newly diagnosed ovarian cancers?: A population-based study",

abstract = "NICE guidance recommends the use of paclitaxel and a platinum therapy for all cases of ovarian cancer. We report our experience of treating 133 patients with ovarian cancer over a 3-year period. Where indicated, 91% received chemotherapy. A taxane/platinum combination was found to be appropriate in 63% of patients only.",

keywords = "Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Carboplatin, Combined Modality Therapy, Female, Humans, Middle Aged, Mixed Tumor, Mullerian, Neoplasm Staging, Neoplasms, Glandular and Epithelial, Ovarian Neoplasms, Paclitaxel, Practice Guidelines as Topic, Prospective Studies, Radiotherapy Dosage, Survival Rate, Taxoids, NICE, Ovarian Cancer , Chemotherapy ",

author = "McNally, {O M} and E Delaney and Petty, {R D} and Cruickshank, {M E} and Hutcheon, {A W} and Parkin, {D E}",

year = "2003",

month = sep,

day = "15",

doi = "10.1038/sj.bjc.6601071",

language = "English",

volume = "89",

pages = "966--967",

journal = "British Journal of Cancer",

issn = "0007-0920",

publisher = "Nature Publishing Group",

number = "6",

}

TY - JOUR

T1 - Is optimal first-line chemotherapy deliverable in all newly diagnosed ovarian cancers?

T2 - A population-based study

AU - McNally, O M

AU - Delaney, E

AU - Petty, R D

AU - Cruickshank, M E

AU - Hutcheon, A W

AU - Parkin, D E

PY - 2003/9/15

Y1 - 2003/9/15

N2 - NICE guidance recommends the use of paclitaxel and a platinum therapy for all cases of ovarian cancer. We report our experience of treating 133 patients with ovarian cancer over a 3-year period. Where indicated, 91% received chemotherapy. A taxane/platinum combination was found to be appropriate in 63% of patients only.

AB - NICE guidance recommends the use of paclitaxel and a platinum therapy for all cases of ovarian cancer. We report our experience of treating 133 patients with ovarian cancer over a 3-year period. Where indicated, 91% received chemotherapy. A taxane/platinum combination was found to be appropriate in 63% of patients only.

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Antineoplastic Combined Chemotherapy Protocols

KW - Carboplatin

KW - Combined Modality Therapy

KW - Female

KW - Humans

KW - Middle Aged

KW - Mixed Tumor, Mullerian

KW - Neoplasm Staging

KW - Neoplasms, Glandular and Epithelial

KW - Ovarian Neoplasms

KW - Paclitaxel

KW - Practice Guidelines as Topic

KW - Prospective Studies

KW - Radiotherapy Dosage

KW - Survival Rate

KW - Taxoids

KW - NICE

KW - Ovarian Cancer

KW - Chemotherapy

U2 - 10.1038/sj.bjc.6601071

DO - 10.1038/sj.bjc.6601071

M3 - Article

C2 - 12966409

SN - 0007-0920

VL - 89

SP - 966

EP - 967

JO - British Journal of Cancer

JF - British Journal of Cancer

IS - 6

ER -